0001213900-20-045225.txt : 20201230 0001213900-20-045225.hdr.sgml : 20201230 20201229180213 ACCESSION NUMBER: 0001213900-20-045225 CONFORMED SUBMISSION TYPE: 1-U PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201222 ITEM INFORMATION: Other Events FILED AS OF DATE: 20201230 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Emerald Health Pharmaceuticals Inc. CENTRAL INDEX KEY: 0001700800 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 820669961 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 1-U SEC ACT: 1933 Act SEC FILE NUMBER: 24R-00152 FILM NUMBER: 201423556 BUSINESS ADDRESS: STREET 1: 5910 PACIFIC CENTER BLVD STREET 2: SUITE 320, CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: (858) 352-0622 MAIL ADDRESS: STREET 1: 5910 PACIFIC CENTER BLVD STREET 2: SUITE 320, CITY: SAN DIEGO STATE: CA ZIP: 92121 1-U 1 ea132409-1u_emeraldhealth.htm 1-U

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 1-U

 

CURRENT REPORT PURSUANT TO REGULATION A

 

Date of Report (Date of earliest event reported): December 22, 2020

 

Emerald Health Pharmaceuticals Inc.

 

(Exact name of issuer as specified in its charter)

 

Delaware

 

State or other jurisdiction of incorporation or organization

 

82-0669961

 

(I.R.S. Employer Identification No.)

 

5910 Pacific Center Blvd., Suite 320, San Diego, CA 92121

 

(Full mailing address of principal executive offices)

 

(858) 352 - 0622

 

(Issuer’s telephone number, including area code)

 

Title of each class of securities issued pursuant to Regulation A: Common Stock

 

 

 

Item 9. Other Events

 

 

Related Party Transaction

 

On December 22, 2020, the Company received written notice of demand from Emerald Health Sciences Inc. (“EHS”), the Company’s majority stockholder, for payment of $750,000 of outstanding principal owed pursuant to the Loan Agreement between EHS, as lender, and the Company, as borrower, dated as of September 1, 2017, as amended on January 26, 2018 and November 15, 2019. The Company made the principal payment to EHS on December 29, 2020.

 

1

 

 

 SIGNATURES

 

Pursuant to the requirements of Regulation A, the issuer has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  EMERALD HEALTH PHARMACEUTICALS INC.,
  a Delaware corporation
   
  By: /s/ James DeMesa
    James DeMesa
    President and Chief Executive Officer

 

Date: December 29, 2020

 

2